If you are:
Only When Necessary: INSUFF HUMAN DATA AVAIL; ANIMAL DATA SHOW DEVELOPMENTAL TOXICITY IN 2ND/3RD TRIM
Precaution: INSUFFICIENT HUMAN DATA AVAILABLE; EXCRETED IN RATS
An adult over 60:
management or monitoring precaution: Renal-Risk for increased creatinine. Risk is highest in pre-existing renal impairment. Poor efficacy shown with CrCL<60 mL/min. Monitor closely and discontinue if CrCL<60mL/min. Urosepsis and pyelonephritis reported in post-marketing studies. Cardiovascular-Dapagliflozin causes an osmotic diuresis which can lead to low intravascular volume, orthostatic blood pressure changes and falls. Endocrine-Ketoacidosis reported with glucose levels lower than expected (<250mg/dL).
Giving dapagliflozin tablet to a child under 12:
management or monitoring precaution: No safety and efficacy established in pediatrics.